UB Paderborn / Katalog / Suche / in CDI

P416 The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i544-i546

2023

Link zum Volltext

Verfügbarkeit prüfen

P661 Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn’s disease: data from the ADVANCE and MOTIVATE studies

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i790-i791

2023

Link zum Volltext

Verfügbarkeit prüfen

DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i190-i190

2024

Link zum Volltext

Verfügbarkeit prüfen

DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i104-i105

2024

Link zum Volltext

Verfügbarkeit prüfen

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1388-i1389

2024

Link zum Volltext

Verfügbarkeit prüfen

OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i048-i048

2022

Link zum Volltext

Verfügbarkeit prüfen

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i560-i560

2023

Link zum Volltext

Verfügbarkeit prüfen

DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i90-i91

2024

Link zum Volltext

Verfügbarkeit prüfen

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i168-i170

2024

Link zum Volltext

Verfügbarkeit prüfen

P544 Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i491-i491

2022

Link zum Volltext

Verfügbarkeit prüfen

DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i127-i128

2022

Link zum Volltext

Verfügbarkeit prüfen

OP25 Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i027-i028

2022

Link zum Volltext

Verfügbarkeit prüfen

P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i381-i382

2022

Link zum Volltext

Verfügbarkeit prüfen

P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i675-i677

2023

Link zum Volltext

Verfügbarkeit prüfen

P322 Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S262-S262

2019

Link zum Volltext

Verfügbarkeit prüfen

DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i125-i126

2022

Link zum Volltext

Verfügbarkeit prüfen

DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i126-i127

2022

Link zum Volltext

Verfügbarkeit prüfen

OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i045-i048

2022

Link zum Volltext

Verfügbarkeit prüfen

DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S057-S057

2019

Link zum Volltext

Verfügbarkeit prüfen

P365 Correlation between patient-reported outcomes (PROs) and patient-reported disease activity in Ulcerative Colitis (UC): Findings from the ICONIC study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S382-S383

2021

Link zum Volltext

Verfügbarkeit prüfen

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Journal of the Canadian Association of Gastroenterology, 2022-02, Vol.5 (Supplement_1), p.43-45

2022

Link zum Volltext

Verfügbarkeit prüfen

Fluorescently tagged laminin subunits facilitate analyses of the properties, assembly and processing of laminins in live and fixed lung epithelial cells and keratinocytes

Matrix biology, 2008-09, Vol.27 (7), p.640-647

2008

Link zum Volltext

Verfügbarkeit prüfen

Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

Journal of Clinical Microbiology, 2000-06, Vol.38 (6), p.2369-2373

2000

Link zum Volltext

Verfügbarkeit prüfen

Desmosomes and Hemidesmosomes

Encyclopedia of Biological Chemistry, 2013, Vol.1, p.636-643

Second Edition, 2013

Link zum Volltext

Verfügbarkeit prüfen

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits : efficacy, safety and non-compartmental pharmacokinetics

Journal of antimicrobial chemotherapy, 1999, Vol.43 (1), p.95-103

1999

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

P416 The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom

P661 Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn’s disease: data from the ADVANCE and MOTIVATE studies

DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial

DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

P544 Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials

DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY

OP25 Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials

P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease

P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

P322 Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC

DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab

DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

P365 Correlation between patient-reported outcomes (PROs) and patient-reported disease activity in Ulcerative Colitis (UC): Findings from the ICONIC study

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Fluorescently tagged laminin subunits facilitate analyses of the properties, assembly and processing of laminins in live and fixed lung epithelial cells and keratinocytes

Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

Desmosomes and Hemidesmosomes

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits : efficacy, safety and non-compartmental pharmacokinetics

Suchergebnisse filtern